Appili Therapeutics Corp.
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring a Phase 3 clinical trial evaluating oral antiviral Avigan® / REEQONUSTM (favipiravir) for the worldwide treatment of COVID-19. The Company’s broader portfolio includes a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two antibiotic programs.